Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)

Yu Zhang, Ziyu Li, Yantao Tian, Jiang Yu, Jieti Wang, Chang‐Min Lee, Kuan Wang, Xianli He, Qing Qiao, Gang Ji, Zekuan Xu, Li Yang, Hao Xu, Xiaohui Du, Xiangqian Su, Jiadi Xing, Zhaojian Niu, Linghua Zhu, Yan Su, Yong Li, Junjiang Wang, Zhengrong Li, Yongliang Zhao, Jun You, Changqing Jing, L F Fan, Yian Du, Gaoping Zhao, Song Wu, Yi Xuan, Mingde Zang, Jie Chen, Sung Soo Park, Hua Huang, The China-Korea Laparoscopic Gastrointestinal Surgery Study (cklass) Cooperative GroupGastric 2024 · DOI

Abstract

This multi-center randomized controlled trial (CKLASS01) compared totally laparoscopic distal gastrectomy (TLDG) with laparoscopy-assisted distal gastrectomy (LADG) for clinical stage I gastric cancer. While both surgical methods demonstrated equivalent safety profiles regarding postoperative morbidity and mortality, TLDG significantly improved short-term quality of life (QoL) and reduced postoperative pain, particularly in patients with a higher body mass index (BMI). These findings suggest that TLDG offers tangible clinical benefits in the early recovery phase without compromising safety.

Introduction

Laparoscopic surgery has become the standard of care for early gastric cancer (EGC). The conventional approach, laparoscopy-assisted distal gastrectomy (LADG), involves internal dissection via camera followed by an extracorporeal anastomosis through a small "mini-laparotomy" incision. However, this mini-incision remains a source of postoperative pain and visible scarring. Totally laparoscopic distal gastrectomy (TLDG) aims to mitigate these issues by performing the entire procedure, including the anastomosis, intracorporeally. Despite its theoretical advantages, TLDG is technically more demanding, and high-quality evidence comparing its outcomes to LADG has been limited. The CKLASS01 trial was designed to evaluate whether TLDG provides superior morbidity and quality of life outcomes compared to the current standard.

Methods

The CKLASS01 trial was a Phase III, multi-center randomized controlled trial conducted across 21 hospitals in China (ClinicalTrials.gov: NCT03393182). A total of 442 patients with clinical stage I gastric cancer were randomized 1:1 to receive either TLDG or LADG. To ensure surgical proficiency, participating surgeons were required to have performed more than 100 laparoscopic gastrectomies.

The primary endpoint was early postoperative morbidity (complications within 30 days). Secondary endpoints included 90-day mortality and longitudinal quality of life (QoL) assessed at 3, 6, and 12 months using the EORTC QLQ-C30 and STO22 questionnaires. Analysis was performed on a modified intention-to-treat (mITT) basis, including 422 patients who completed the assigned surgical procedure.

CONSORT flow diagram showing the randomization and analysis of 442 patients.

Results

Safety and Morbidity

The study found no significant difference in early postoperative morbidity between the two groups (TLDG: 6.0% vs. LADG: 5.8%, $P=0.93$). Mortality rates at 90 days were also comparable (TLDG: 0.5% vs. LADG: 0.0%, $P>0.99$). These results indicate that in expert hands, the intracorporeal anastomosis of TLDG is as safe and reliable as the extracorporeal approach of LADG.

Postoperative Pain and BMI

A significant advantage for TLDG was observed in patients with a BMI $\ge$ 25 kg/m². In this subgroup, TLDG patients reported significantly lower pain scores at 24 hours post-surgery ($P=0.002$). This benefit likely stems from avoiding the trauma associated with a mini-laparotomy in patients with a thicker abdominal wall.

Quality of Life and Body Image

TLDG patients reported superior quality of life metrics in the early postoperative period. Specifically, TLDG was associated with better social functioning at 3 months ($P=0.03$) and 6 months ($P=0.04$), as well as improved global health status at 3 months ($P=0.02$). Furthermore, TLDG patients had significantly better "body image" scores at 3 months ($P=0.01$), likely due to the absence of a visible upper abdominal scar, as the extraction site in TLDG is often hidden in the umbilicus.

Discussion and Conclusion

The CKLASS01 trial demonstrates that TLDG provides significant short-term benefits over LADG. While long-term functional outcomes (at 12 months) and safety profiles are similar, the reduction in early postoperative pain and the psychological benefit of improved body image make TLDG a compelling option for EGC treatment.

Limitations of this study include a focus on short-term outcomes; long-term oncologic data (5-year survival) are still pending. Additionally, the exclusion of Billroth I reconstructions may limit generalizability to all surgical practices. Despite these factors, the trial confirms that TLDG is a safe and effective technique that enhances the patient's recovery experience, particularly for those with higher BMI, making it a preferred minimally invasive approach in expert centers.

Summary updated

BibTeX
@inproceedings{zhang2024morbidity,
  author = {Yu Zhang and Ziyu Li and Yantao Tian and Jiang Yu and Jieti Wang and Chang‐Min Lee and Kuan Wang and Xianli He and Qing Qiao and Gang Ji and Zekuan Xu and Li Yang and Hao Xu and Xiaohui Du and Xiangqian Su and Jiadi Xing and Zhaojian Niu and Linghua Zhu and Yan Su and Yong Li and Junjiang Wang and Zhengrong Li and Yongliang Zhao and Jun You and Changqing Jing and L F Fan and Yian Du and Gaoping Zhao and Song Wu and Yi Xuan and Mingde Zang and Jie Chen and Sung Soo Park and Hua Huang and The China-Korea Laparoscopic Gastrointestinal Surgery Study (CKLASS) Cooperative Group},
  title = {{Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)}},
  booktitle = {Gastric},
  year = {2024},
  doi = {10.1007/s10120-024-01561-y},
}
Figure